Experimental dual SGLT inhibitor cut HbA1c and weight

Many people with type 2 diabetes remain above their glucose targets despite doing the diet and exercise work, and the usual next step is medication. Sodium-glucose co-transporter inhibitors work by interfering with glucose transport, and JP-2266 is designed to block both SGLT1 and SGLT2 rather than SGLT2 alone. Whether that dual action delivers meaningful glycaemic control, and whether it is tolerated well enough to justify larger studies, is precisely the question a phase 2 trial exists to answer. Early-phase results like these shape which drugs progress and which are abandoned.

The trial was a 12-week, randomised, double-blind, placebo-controlled phase 2 study in 156 patients with type 2 diabetes inadequately controlled with diet and exercise. Participants were assigned 1:1:1 to once-daily JP-2266 at 5 mg (n=51), 10 mg (n=53) or placebo (n=52). The primary endpoint was the change in HbA1c from baseline to week 12. Secondary measures included fasting plasma glucose, postprandial glucose, body weight, systolic blood pressure, and homeostasis model assessment estimates of insulin resistance and beta-cell function, with adverse events recorded throughout.

Placebo-adjusted HbA1c fell by 0.94% on the 5 mg dose and 0.97% on the 10 mg dose, both highly significant. Fasting plasma glucose dropped by 36.22 mg/dL at 5 mg and 39.38 mg/dL at 10 mg, and postprandial glucose by 62.30 mg/dL and 66.89 mg/dL respectively. Body weight fell by 2.0 to 2.1 kg, and systolic blood pressure by 3.6 mm Hg on the 10 mg dose. Insulin resistance and beta-cell function indices improved, and adverse event rates were similar to placebo. Notably, doubling the dose added very little on the primary endpoint.

This is an early efficacy signal rather than a settled result. The near-identical HbA1c effect at both doses suggests the response may already be close to a plateau at the lower dose, which matters for later dose selection. The trial had no active comparator, so nothing here shows whether dual SGLT1/SGLT2 inhibition beats existing options. Twelve weeks is also too short to say anything about cardiovascular, kidney or long-term safety outcomes, and the study population was recruited at Korean centres, leaving generalisability open.

For anyone tracking the diabetes drug pipeline, this is a reason to think dual SGLT1/SGLT2 inhibition can meaningfully move glucose control, body weight and blood pressure over three months in people not yet on medication. It is not a product anyone can obtain, and it says nothing about how it would compare with what is already prescribed. The modest weight and blood pressure changes are the kind of secondary benefits also reported with this drug class more broadly. Treat it as a promising early step that now needs longer, larger and comparative trials.